News stories about Intellipharmaceutics International (NASDAQ:IPCI) (TSE:I) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intellipharmaceutics International earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave news headlines about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near future.
Shares of Intellipharmaceutics International (IPCI) traded down 3.21% during midday trading on Wednesday, hitting $2.71. The stock had a trading volume of 136,415 shares. Intellipharmaceutics International has a 1-year low of $1.53 and a 1-year high of $3.35. The firm’s market capitalization is $82.35 million. The company’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.39.
Several research firms recently commented on IPCI. Zacks Investment Research cut Intellipharmaceutics International from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the company a “buy” rating in a research note on Thursday, May 11th. Aegis reaffirmed a “hold” rating and issued a $2.00 target price on shares of Intellipharmaceutics International in a research report on Tuesday, April 18th. Finally, ValuEngine upgraded Intellipharmaceutics International from a “sell” rating to a “hold” rating in a report on Friday, May 26th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $4.63.
ILLEGAL ACTIVITY WARNING: “Intellipharmaceutics International (NASDAQ:IPCI) Getting Somewhat Positive Media Coverage, Accern Reports” was originally reported by BBNS and is the property of of BBNS. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://baseballnewssource.com/markets/intellipharmaceutics-international-ipci-given-news-impact-score-of-0-25-updated-updated/1072742.html.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with our FREE daily email newsletter.